Boehringer Ingelheim, Evotec and bioMérieux forms JV Aurobac to fight antimicrobial resistance
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
The vaccine is under FDA review
Meets the growing need for US-based API solubility and bioavailability enhancement services
Strengthens investment in channels of the future to expand patient reach
Both vaccine candidates demonstrated a favorable safety and tolerability profile similar to the Pfizer-BioNTech COVID-19 Vaccine
The company has launched indigenously produced Dual Chamber Bags of global standards in India at a pocket-friendly price
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Govt. has set a target to increase the number of JanAushadhi Kendras to 10,000 by March 2024
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Subscribe To Our Newsletter & Stay Updated